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i.org/1(NOAF) in transcatheter aortic valve implantation (TAVI) remain uncertain. This study
assesses the epidemiology of AF in patients treated with TAVI and evaluates their outcomes
according to the presence of preexisting AF or NOAF. A retrospective analysis of 708
patients undergoing TAVI from 2 heart hospitals was performed. Patients were divided into
3 study groups: sinus rhythm (n [ 423), preexisting AF (n [ 219), and NOAF (n [ 66).
Primary outcomes of interest were all-cause death and stroke both at 30-day and at 1-year
follow-up. Preexisting AF was present in 30.9% of our study population, whereas NOAF
was observed in 9.3% of patients after TAVI. AF and NOAF patients showed a higher rate
of 1-year all-cause mortality compared with patients in sinus rhythm (14.6% vs 6.5% for
preexisting AF and 16.3% vs 6.5% for NOAF, p [ 0.007). No differences in 30-day
mortality were observed between groups. In patients with AF (either preexisting and
new-onset), those discharged with single antiplatelet therapy displayed higher mortality
rates at 1 year (42.9% vs 11.7%, p [ 0.006). Preexisting AF remained an independent
predictor of mortality at 1-year follow-up (hazard ratio [HR] 2.34, 95% CI 1.22 to 4.48,
p[ 0.010). Independent predictors of NOAF were transapical and transaortic approach as
well as balloon postdilatation (HR 3.48, 95% CI 1.66 to 7.29, p [ 0.001; HR 5.08, 95% CI
2.08 to 12.39, p <0.001; HR 2.76, 95% CI 1.25 to 6.08, p [ 0.012, respectively). In
conclusion, preexisting AF is common in patients undergoing TAVI and is associated with a
twofold increased risk of 1-year mortality. This negative effect is most pronounced in
patients discharged with single antiplatelet therapy compared with other antithrombotic
regimens.  2016 Elsevier Inc. All rights reserved. (Am J Cardiol 2016;118:1527e1532)Transcatheter aortic valve implantation (TAVI) is an
established treatment for patients with aortic stenosis (AS)
who are inoperable or at high risk for surgery.1,2 A sub-
stantial proportion of patients who are scheduled for TAVI
are noted to have atrial ﬁbrillation (AF) at the time of the
screening for eligibility for TAVI.3 Indeed, AF and AS
coexist with a prevalence that varies from 16% to 40%.4
Moreover, new-onset AF (NOAF) is a frequent ﬁnding in
the postoperative period after TAVI, with an incidence
ranging from 0.7% to 31.9%.5 Population-based studies
indicate an increased risk of stroke and systemic embolism
as well as impaired long-term survival of subjects with AF
compared with those with normal sinus rhythm (SR).6 In thef Cardiology, Baylor University Medical Center, Baylor
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0.1016/j.amjcard.2016.08.017general population, AF is estimated to increase the risk of
death 1.5-fold in men and 1.9-fold in women.7 AF is a well-
established predictor of adverse outcomes in patients with
AS, and several previous studies demonstrated increased
risk for mortality related to AF in patients undergoing open-
chest valve surgery.8,9 Similarly, NOAF is associated with
overall and late mortality after coronary artery bypass graft,
perioperative complications, and 30-day mortality and ce-
rebrovascular events (CVE) in patients with postmyocardial
infarction.10 However, data on the prevalence and impact of
preexisting AF or NOAF in the setting of TAVI are scant
and limited to retrospective studies that have speciﬁcally
focused on this issue.11e15 In the present study, we sought
to evaluate the epidemiology, predictors, management, and
prognostic implications of AF, either preexisting or new-
onset, in patients who underwent TAVI.Methods
Data were collected on consecutive patients with severe,
symptomatic AS undergoing TAVI at Baylor Heart and
Vascular Hospital (Dallas, Texas) and the Heart Hospital
Baylor Plano (Plano, Texas) from January 2012 to August
2015. Baseline demographics, procedural data, and clinical
outcomes were retrospectively collected and analyzed. Forwww.ajconline.org
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Age (years), mean  SD 81.97.8 80.98.3 83.46.6 83.17.7 0.001
Men 341 (54.4%) 231 (54.6%) 128 (58.4%) 28 (42.4%) 0.072
Body Mass Index (kg/m2), median (IQR) 27.912.9 28.415.9 26.85.9 28.98.1 ns
Hypertension 574 (82.2%) 352 (84.0%) 167 (78.0%) 56 (84.8%) ns
Hyperlipidemia 481 (69.6%) 293 (70.9%) 150 (70.1%) 39 (60.0%) ns
Diabetes 265 (40.1%) 165 (42.0%) 74 (36.3%) 26 (40.0%) ns
Chronic kidney disease 345 (49.6%) 207 (50.0%) 109 (50.2%) 29 (43.9%) ns
End stage renal disease 22 (3.5%) 13 (3.5%) 7 (3.6%) 2 (3.1%) ns
Coronary artery disease 475 (68.2%) 291 (70.3%) 140 (64.2%) 44 (67.7%) ns
Peripheral arterial disease 225 (34.0%) 140 (35.4%) 65 (32.0%) 20 (31.7%) ns
COPD 132 (20.8%) 81 (21.4%) 36 (18.5%) 15 (23.8%) ns
Previous CABG/PCI 296 (44.6%) 176 (44.1%) 91 (45.3%) 29 (45.3%) ns
Previous CVE 124 (19.5%) 60 (16.1%) 54 (26.7%) 10 (15.9%) 0.007
Echocardiographic ﬁndings
Left ventricle ejection fraction (%), mean  SD 54.613.0 55.013.1 53.313.1 55.712.7 ns
Stroke Volume indexed (ml/m2), mean  SD 37.612.0 38.612.3 34.811.4 40.810.3 <0.0001
Aortic valve mean gradient (mmHg), mean  SD 44.113.6 44.413.5 43.314.1 44.812.6 ns
Aortic valve area (cm2), mean  SD 0.680.18 0.690.18 0.660.18 0.610.18 0.054
Procedural characteristics
Type of Valve ns
Balloon-expandable 451 (63.8%) 264 (62.4%) 142 (64.8%) 46 (69.7%) ns
Self-expandable 256 (36.2%) 159 (37.6%) 77 (35.2%) 20 (30.3%) ns
Approach <0.0001
Trans-femoral 610 (86.3%) 376 (88.9%) 192 (87.7%) 43 (65.2%)
Trans-apical 65 (9.2%) 33 (7.8%) 17 (7.8%) 15 (22.7%)
Trans-aortic 28 (4.0%) 11 (2.6%) 10 (4.6%) 7 (10.6%)
Subclavian 4 (0.6%) 3 (0.7%) 0 (0.0%) 1 (1.5%)
Post-operative Drugs <0.0001
DAPT 426 (61.0%) 315(75.2%) 77 (35.8%) 34 (53.1%)
OAT 133 (19.1%) 25 (6.0%) 92 (42.8%) 16 (25.0%)
DAPTþOAT 40 (5.7%) 4 (1.0%) 28 (13.0%) 8 (12.5%)
Single antiplatelet therapy 99 (14.2%) 75 (17.9%) 18 (8.4%) 6 (9.4%)
AF ¼ atrial ﬁbrillation; CABG ¼ coronary aortic bypass graft; COPD ¼ chronic obstructive pulmonary disease; CVE ¼ cerebrovascular events; DAPT ¼
double antiplatelet therapy; IQR ¼ interquartile range; NOAF ¼ new-onset atrial ﬁbrillation; OAT ¼ oral anticoagulant therapy; PCI ¼ percutaneous coronary
intervention; SD ¼ standard deviation.
1528 The American Journal of Cardiology (www.ajconline.org)the purpose of the current analysis, data from both medical
centers were pooled, and a joint database was created. The
study was approved by the Baylor Institutional Review
Board.
Preexisting AF was diagnosed based on clinical history
and/or on a 12-lead electrocardiogram performed before
TAVI. NOAF was deﬁned as any episode of AF occurring
within 30 days after TAVI in a patient with no previous
known AF, lasting long enough to be recorded on a 12-lead
electrocardiogram or at least 30 seconds on a rhythm
strip.11,16,17 All study end points were deﬁned according to
Valve Academic Research Consortium deﬁnitions.18 The
primary outcomes of interest were all-cause death and stroke
both at 30-day and at 1-year follow-up. Secondary measures
included in-hospital mortality and minor, major, and life-
threatening bleedings.
Continuous variables are summarized as mean  SD or
as medians and interquartile range as appropriate and were
compared using the Student t test or ManneWhitney rank-
sum test. Categorical variables were compared using the
chi-square or the Fisher’s exact test. Binary logisticregression was used for the prediction of NOAF and 1-year
all-cause mortality in the whole population as well as in
patients with AF, respectively, as dependent variables,
whereas baseline variables of clinical interest and/or
satisfaction of the entry criterion of p <0.05 in the uni-
variable analysis were used as explanatory variables. Sur-
vival curves were constructed using KaplaneMeier
estimates, whereas comparisons relied on the log-rank test.
A 2-sided alpha level of 0.05 was used for all superiority
testing. All statistical analyses were performed using SPSS
(version 19) statistical software (SPSS, Inc., Chicago,
Illinois).
Results
The study population consisted of 708 patients who un-
derwent TAVI, divided in 3 study groups: patients in SR up
to 30 days after TAVI and without any history of AF
(n ¼ 423), patients with preexisting AF (n ¼ 219), and
patients with NOAF (n ¼ 66). The baseline characteristics,












In-hospital mortality 11 (1.6%) 5 (1.2%) 5 (2.3%) 1 (1.5%) 0.564
Bleeding 0.666
Minor 45 (6.4%) 23 (5.5%) 18 (8.2%) 4 (6.1%)
Major and life-threatening 10 (1.4%) 7 (1.7%) 2 (0.9%) 1 (1.5%)
30-day outcomes
Stroke/TIA 17 (2.4%) 9 (2.1%) 5 (2.3%) 3 (4.5%) 0.486
All-cause mortality 21 (3.0%) 9 (2.1%) 10 (4.6%) 2 (3.0%) 0.225
1-year outcomes
Stroke/TIA 24 (4.6%) 12 (3.9%) 7 (4.3%) 5 (10.2%) 0.147
All-cause mortality 51 (9.9%) 20 (6.5%) 23 (14.6%) 8 (16.3%) 0.007
AF ¼ atrial ﬁbrillation; TIA ¼ transient ischemic attack.
Table 3
Stratiﬁed analysis according to discharge therapy in patients with atrial
ﬁbrillation for all-cause mortality at 1 year
Variable n Event HR, 95% CI p
Single Anti-Platelet Therapy 14 6 (42.9%) reference -
Multiple anti-thrombotic therapy 188 22 (11.7%) 0.18 (0.06-0.56) 0.003
DAPT 84 11 (13.1%) 0.20 (0.06-0.69) 0.011
OAT 74 6 (8.1%) 0.12 (0.03-0.45) 0.002
DAPTþOAT 30 5 (16.7%) 0.27 (0.06-1.11) 0.070
CI ¼ conﬁdence interval; DAPT ¼ double antiplatelet therapy; HR ¼
hazard ratio; OAT ¼ oral anticoagulant therapy.
Table 4
Stratiﬁed analysis according to type of atrial ﬁbrillation for all-cause
mortality at 1 year
Rhythm n Event HR, 95% CI p
Sinus Rhythm 306 20 (6.5%) reference
Permanent AF 147 21 (14.3%) 2.38 (1.25-4.55) 0.009
Persistent AF 1 0 -
Paroxysmal AF 5 0 -
Atrial Flutter 5 2 (40.0%) 9.53 (1.50-60.37) 0.017
NOAF 49 8 (16.3%) 2.79 (1.15-6.75) 0.023
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; HR ¼ hazard ratio;
NOAF ¼ new-onset atrial ﬁbrillation.
Valvular Heart Disease/Atrial Fibrillation and TAVI Outcomes 1529listed in Table 1. The observed prevalence of preexisting AF
(paroxysmal, persistent, or permanent) in our study popu-
lation was 30.9%. Patients with preexisting AF displayed a
higher prevalence of previous CVE, had a lower stroke
volume index (SVi), and were signiﬁcantly older than pa-
tients in SR. NOAF was observed in 66 patients (9.3%). A
signiﬁcantly higher incidence of NOAF was observed in
patients treated using the transapical, transaortic, or other
approaches compared with those treated using the trans-
femoral approach (23.1%, 28.6%, and 25.0% vs 7.2%,
respectively; p <0.001).
Clinical outcomes are described in Table 2. Patients
with preexisting AF and patients with NOAF showed a
higher rate of 1-year all-cause mortality compared with
patients in SR (14.6% vs 6.5% for preexisting AF and
16.3% vs 6.5% for NOAF, p ¼ 0.007, Table 2). In-hospitaland 30-day mortality rates, 30-day and 1-year stroke/
transient ischemic attack rate and bleeding were similar
between groups (Table 2). When looking at patients with
AF, those discharged with single antiplatelet therapy dis-
played higher mortality rates at 1 year compared with
patients treated with dual antiplatelet therapy or antico-
agulants (42.9% vs 11.7%, p ¼ 0.011; Table 3). Table 4
reports number of events and hazard ratio (HR; 95% CI)
for each type of AF; permanent AF, atrial ﬂutter, and
NOAF were associated with a signiﬁcantly higher rate of
1-year all-cause mortality (HR 2.38, 95% CI 1.25 to 4.55,
p ¼ 0.009; HR 9.53, 95% CI 1.50 to 60.37, p ¼ 0.017; HR
2.79, 95% CI 1.15 to 6.75, p ¼ 0.023, respectively). The
event-free survival curves at 1 year of patients treated by
TAVI according to the presence of AF (either preexisting
and new-onset) are shown in Figure 1. Overall, patients
with AF (either preexisting or new-onset) had worse out-
comes compared with those in SR in terms of all-cause
mortality (log-rank ¼ 0.008; Figure 1). Survival curves
of patients with AF (either preexisiting or new-onset) ac-
cording to the antithrombotic discharge regimen are shown
in Figure 1. AF patients discharged with single antiplatelet
therapy displayed the worst survival at 1-year follow-up
(log-rank ¼ 0.003; Figure 1).
Predictors of 1-year all-cause mortality are reported in
Table 5. In the total population, male gender and preexisting
AF are both independent predictors of mortality at 1-year
follow-up (HR 2.05, 95% CI 1.07 to 3.90, p ¼ 0.029; HR
2.34, 95% CI 1.22 to 4.48, p ¼ 0.010, respectively).
Moreover, the use of a transfemoral approach showed a
signiﬁcant protective role on mortality at 1 year (HR 0.34,
95% CI 0.16 to 0.73, p ¼ 0.006). Table 5 reports the
multivariable analysis for 1-year all-cause mortality in pa-
tients with AF as well. As shown, single antiplatelet therapy
and a transfemoral approach remained the only independent
predictors of 1-year mortality in patients with AF (HR 4.25,
95% CI 1.17 to 15.4, p ¼ 0.028; HR 0.28, 95% CI 0.10 to
0.78, p ¼ 0.015, respectively).
Predictors of the incidence of NOAF are reported in
Table 6. The use of transapical and transaortic approach as
well as balloon postdilatation resulted as independent pre-
dictors of NOAF (HR 3.48, 95% CI 1.66 to 7.29, p ¼ 0.001;
HR 5.08, 95% CI 2.08 to 12.39, p <0.001; HR 2.76, 95%
CI 1.25 to 6.08, p ¼ 0.012, respectively).
Figure 1. KaplaneMeier survival curves. (A) 1-year survival according to group rhythm. (B) 1-year survival according to the discharge antithrombotic therapy
in patients with AF.
Table 5
Predictors of all-cause mortality at 1 year in the total population and in the
atrial ﬁbrillation patients
Variable Multivariate Analysis
HR (95% CI) p
All Patients
Male sex 2.05 (1.07-3.90) 0.029
Chronic kidney disease 1.79 (0.97-3.30) 0.060
Pre-existing Atrial Fibrillation 2.34 (1.22-4.48) 0.010
New-Onset Atrial Fibrillation 2.15 (0.82-5.64) 0.119
Atrial ﬁbrillation patients
Age 1.00 (0.94-1.07) 0.923
LVEF
For each 1 unit increase
1.02 (0.98-1.06) 0.328
Thrombocytopenia
For each 1 unit increase
0.99 (0.98-1.00) 0.212
Single Anti-Platelet Therapy 4.25 (1.17-15.4) 0.028
Trans-femoral Approach 0.28 (0.10-0.78) 0.015
Trans-femoral Approach 0.34 (0.16-0.73) 0.006
Statistically signiﬁcant values are shown in bold type.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
Table 6
Predictors of new-onset atrial ﬁbrillation
Multivariate Analysis
HR (95% CI) p
Age 1.03 (0.99-1.07) 0.105
Body Mass Index (kg/m2)
For each 1 unit increase
1.01 (0.99-1.02) 0.190
Stroke Volume Indexed (ml/m2)
For each 1 unit increase
1.02 (0.99-1.04) 0.057
Self-expandable Valve 2.07 (0.93-4.58) 0.074
Balloon post-dilatation 2.76 (1.25-6.08) 0.012
Trans-apical Approach 3.48 (1.66-7.29) 0.001
Trans-Aortic Approach 5.08 (2.08-12.39) <0.001
Trans-Subclavian 6.00 (0.48-74.87) 0.164
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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The present study adds to the current knowledge that (1)
preexisting AF is a common condition among high-risk
elderly patients undergoing TAVI, with a prevalence of
30.9% in this patient population; (2) preexisting AF is
associated with a signiﬁcantly increased risk of all-cause
mortality at 1-year follow-up, whereas it does not seem to
represent a risk factor for 30-day all-cause mortality or for
short- and long-term stroke; (3) NOAF occurred in 9.3% of
patients after TAVI, with a particularly higher incidence in
those treated with a transapical or transaortic approach and
with a balloon postdilatation; NOAF, however, was not an
independent predictor of mortality in our cohort; and (4)
Patients with AF discharged with single antiplatelet therapy
post-TAVI have worse 1-year survival compared with other
antithrombotic regimens.AF has a high prevalence in patients with severe AS. It
is well established that AF is a major predictor of death,
stroke, and congestive heart failure in cardiac surgery.6
Unfortunately, only a few conﬂicting small studies have
assessed the epidemiology and clinical impact of AF in
TAVI-treated patients.19 Indeed, in 2 small series of pa-
tients undergoing TAVI, Nuis et al13 and Amat-Santos
et al11 observed a signiﬁcant direct correlation between
NOAF and stroke only. Conversely, Yankelson et al14 and
Barbash et al12 found that preexisting AF, but not NOAF,
increased the rate of mortality and stroke at 1 year. Finally,
Stortecky et al5 and Nombela-Franco et al3 found that both
NOAF and preexisting AF increased the risk for ischemic
cardiac and cerebrovascular events at follow-up. A recent
meta-analysis, including these studies, concluded that AF
was associated with a signiﬁcantly increased risk of all-
cause mortality at long-term follow-up, whereas NOAF
was associated with increased risk of stroke.20 An updated
version of this meta-analysis identiﬁed NOAF as linked to
higher mortality rates both at 30-day and 1-year post-
TAVI.21 Similarly, a recent report from the SOURCE XT
(SAPIEN XT Aortic Bioprosthesis Multi-Region Outcome
Valvular Heart Disease/Atrial Fibrillation and TAVI Outcomes 1531Registry) registry concluded that the presence of either
preexisting or NOAF increased all-cause and cardiac
mortality and bleeding events and that NOAF was asso-
ciated with increased stroke rates at long-term follow-up.
However, therapy data were not reported.15
Our study conﬁrms the observations about preexisting
AF and all-cause mortality. Similarly, our study corrobo-
rates a link between NOAF and stroke reported by previous
reports.11,22,23 We found, indeed, that the event rate tren-
ded higher, although not signiﬁcantly, in patients with
NOAF at short- and long-term follow-up. In contrast, in
our cohort, patients with preexisting AF did not experience
a higher incidence of new CVE, compared with patients in
SR. First, it is possible that patients with AF were treated
more aggressively with antithrombotic drugs, thus
lowering the risk of stroke; second, it is important to un-
derline that patients undergoing TAVI are already at
increased risk for stroke. Moreover, we cannot exclude an
underestimation of AF rate or some overlap between the
NOAF and preexisting AF groups because of the limited
sensitivity of the methods used in clinical practice to assess
AF. In our cohort, systematic 72-hour continuous post-
TAVR electrocardiographic monitoring was not routinely
performed.
The association between transapical access and NOAF
has been already reported and has been previously
attributed to epicardial and pericardial injury, similar to
that occurring in cardiac surgery.24 This supports the
current paradigm that transfemoral access provides the
best outcomes and is the favored approach.25,26 The
continued reduction in delivery size now allows trans-
femoral access in greater than 90% of patients.27 Balloon
postdilation is an another independent procedural pre-
dictor of NOAF observed in this study, as well in other
previous reports.15 However, we found no association of
NOAF with the presence of moderate/severe post-
procedural paravalvular leak, perhaps because moderate/
severe paravalvular leak is less common with new gen-
eration devices.25
The results of this study show that the patients with the
worst survival after TAVI are those in AF (either preex-
isting or new-onset) that have been discharged with single
antiplatelet therapy. Despite the belief that there was a
contraindication to DAPT or oral anticoagulant therapy
(such as thrombocytopenia, fall risk, high bleeding risk,
and so on), patients with AF discharged on single anti-
platelet therapy had the worst outcome of any of the
groups. Even after adjusting for potential cofounders being
discharged with single antiplatelet therapy remained an
independent predictor of mortality (Table 6). This raises
the question of whether this patient population would
beneﬁt from a more aggressive antithrombotic therapy
despite the higher risk proﬁle. Data from prospective
studies or registries are needed to assess and compare
alternative treatment strategies and regimens to reduce the
risk of mortality. Of note, this result came from a small
number of patients and should therefore be considered as
hypothesis generating. Moreover, the study design (retro-
spective and observational) carries all the limitations
inherent to such an investigation.Disclosures
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